Blog dedicated to the continuous education in Gynecology and Endocrinology

 

RELATION OF BODY FAT DISTRIBUTION TO FEMORAL NECK BONE DENSITY AND ENDOMETRIAL THICKNESS IN POSTMENOPAUSAL WOMEN

Oktem DGYE-2009-0167.r1 [ID 463729] 5 PAG

Objective: Menopause is associated with accelerated bone loss, a decrease in lean mass, an increase and redistribution of fat mass in the trunk region. Trunk obesity has been considered as a risk factor for endometrial cancer. We aimed to determine if body composition and fat distribution are determinants of femoral neck bone mineral density (BMD) and endometrial thickness in healthy postmenopausal women.
Study Design: Subjects were 40 healthy postmenopausal women with biopsy proven atrophic endometrium. Anthropometrical variables (total fat mass, trunk and leg fat masses, lean body mass and femoral neck BMD) were measured by dual energy x-ray absorptiometry (DEXA).
Results: Femoral neck BMD was positively correlated with BMI, total fat mass, trunk fat mass, leg fat mass and endometrial thickness, and negatively correlated with age, years since menopause and FSH levels. Trunk fat and age remained significant determinants of femoral neck BMD (R2=32.9 %, p<. 001) and endometrial thickness was significantly associated with femoral neck BMD and estradiol levels (R2= 46.5%, p<. 0001) on regression analysis.
Conclusion: Truncal adiposity rather than overall adiposity or lean mass are more closely associated with femoral neck BMD and there is no relationship between subcutaneous fat mass and endometrial thickness in postmenopausal women.

Post to Twitter Post to Facebook

HRT and CVS – an update

powered by WordPress Multibox Plugin v1.3.5


HRT and CVS – an update
Siseles Nestor

(14th World Congress of Gynecological Endocrinology – March 4-7 2010)

Post to Twitter Post to Facebook

HIGH INTERNAL CONSISTENCY AND EFFICACY OF INTRAVAGINAL DHEA FOR VAGINAL ATROPHY.

Labrie Fernand – DGYE-2009-0199 [ID 451587]

Following the compelling data obtained in a pivotal phase III clinical trial performed in 218 postmenopausal women suffering from vaginal atrophy who received daily intravaginal 0.25%, 0.5% or 1.0% DHEA ovules for 12 weeks, we have performed analysis of the 4 co-primary objectives at each site of that multicenter U.S. and Canadian trial. Comparison was made of the change in % of parabasal and superficial cells, vaginal pH and severity of the most bothersome symptom. The site-by-site (7 sites) analysis has shown that 10 to 13 women per group are generally sufficient to obtain a significant or highly statistically significant decrease in vaginal pH and % of parabasal cells and increase % of superficial cells at p values ranging from 0.02 to <0.0001. For vaginal pain as the most bothersome symptom, a statistically significant difference from baseline was found at 6 out of 7 sites. The exceptionally high consistency between all sites in this phase III study and high potency of the compound permit to obtain a clinically and statistically significant to highly significant effect of treatment with the 0.5% DHEA daily intravaginal dose which does not significantly affect the serum levels of estrogens, thus avoiding systemic risks.

Post to Twitter Post to Facebook

GABAPENTIN VS. LOW DOSE TRANSDERMAL ESTRADIOL FOR TREATING POSTMENOPAUSAL WOMEN WITH MODERATE TO VERY SEVERE HOT FLUSHES

Chedraui Peter – DGYE-2009-0192 [ID 451586]

Objective. Compare GPT vs. low dose transdermal estradiol (E2) for treating postmenopausal women with moderate to very severe hot flushes.
Methods. A total of 45 postmenopausal women with moderate to very severe hot flushes were prospectively and single-blindly randomized to receive oral GPT 600 mg/night or transdermal 25 µg/day E2 per week. Hot flush intensity and frequency were assessed with the Menopause Rating Scale (MRS) and a numeric scale respectively at baseline and at one, four and eight weeks. Side effects were also assessed.
Results. Hot flush intensity and frequency significantly decreased for both groups at one, four and eight weeks of treatment as compared to baseline; however this decrease was statistically more evident for the E2 group. Although the percentage of hot flush intensity and frequency reduction at the end of the treatment was higher for E2, this was not statistically significant (68.2% vs. 60.6% for intensity and 70.1% vs. 58.9% for frequency, respectively, p> 0.05, NS). Encountered side effects included: drowsiness, dizziness, fatigue (GPT group) and mastodynia, vaginal spotting and a local allergic reaction (E2 group). Compliance to treatment was 95.6% (GPT group) as compared to 90.9% for the E2 group.
Conclusion. GPT 600 mg was as effective as low dose transdermal E2 in controlling moderate to severe hot flushes in postmenopausal women.

Post to Twitter Post to Facebook

Personalized therapies in postmenopausal women

powered by WordPress Multibox Plugin v1.3.5


Personalized therapies in postmenopausal women
Gambacciani Marco

(14th World Congress of Gynecological Endocrinology – March 4-7 2010)

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy